What does U.S. Physical Therapy do and what are its main business segments?

What is U.S. Physical Therapy's latest dividend and current dividend yield?

What is U.S. Physical Therapy's gross profit margin?

What is the revenue and EPS growth rate for U.S. Physical Therapy year over year?

What guidance did U.S. Physical Therapy's management provide for the next earnings period?

Did U.S. Physical Therapy beat or miss consensus estimates last quarter?

What were the key takeaways from U.S. Physical Therapy’s earnings call?

What were the key takeaways from U.S. Physical Therapy's earnings call?

- **Record financial performance**: 2025 revenue +16.3%, EBITDA +16.2%, Q4 gross profit +25% YoY.
- **Strategic hospital partnerships**: $14 million EBITDA contribution by 2027, exclusive agreements driving margin expansion.
- **2026 growth drivers**: AI documentation, virtual front desk, Medicare rate hike ($2.5M boost), and hospital partnerships phasing in mid-2026.
- **Cost discipline**: 2025 operating costs per visit down 0.6%, 2026 salary budget reflects controlled inflation.

**【CEO Summary Section】**
- **Year-over-year growth**: 2025 revenue increased 16.3%, with adjusted EBITDA up 16.2% to $95 million. Q4 gross profit rose 25% YoY.
- **Strategic acquisitions**: Added 3 new entities, including a Pacific Northwest home care provider and an injury prevention team, enhancing NYC market presence.
- **Hospital partnerships**: 2 long-term agreements expected to contribute $14 million in EBITDA by 2027, with USPH's share at $7.3 million. Phase-in begins mid-2026.
- **2026 initiatives**: Rollout of AI-driven documentation, virtual front desk, cash-based programs, and remote therapeutic monitoring.

**【CFO Financial Commentary】**
- **Q4 2025 results**: Net revenue $173.8 million (13% YoY), adjusted EBITDA $24.8 million (+$3 million YoY). Full-year visits up 11.2%, net rate per visit +1% to $105.76.
- **Cost control**: Operating costs per visit down 0.6% to $85.56. Physical therapy gross margin 20.5% (up 200bps YoY).
- **2026 guidance**: Adjusted EBITDA $102-106 million, including $2.5 million from Medicare rate hike. Hospital partnerships to drive margin expansion post-2026.

**【Q&A Key Highlights】**
- **Hospital partnerships**: Exclusive agreements with hospitals, offering higher rates than traditional PT. 2027 EBITDA contribution of $14 million reflects current volumes, with potential upside from new facilities.
- **Wage inflation**: 2026 salary budget includes normal inflation, with 2025 cost control sustained through per-visit cost reduction.
- **Volume outlook**: Mature clinics saw 1.5% Q4 visit growth, driven by virtual front desk efficiency. 2026 same-store revenue expected +2.5-3%.
- **M&A strategy**: Preference for injury prevention deals (better margins) but active in PT, targeting Metro-like acquisitions in key markets.

U.S. Physical Therapy, Inc.(USPH)-20260226-2025 Q4 Earnings call transcript

- **Revenue Growth**: 17.8% YoY to $168.1M, driven by 84 new clinics and 18% visit growth
- **Cost Efficiency**: Salaries per visit down $0.40 YoY, operating margin 18.6%
- **Medicare 2026**: 1.5-1.7% rate hike + RTM expansion
- **AI & Automation**: Virtual front desk in 50% of clinics, reducing wait times 30%
- **De Novo Pipeline**: 30-50 new clinics/year, constrained by leadership
- **IIP Outperformance**: 15% revenue growth, 11% EBITDA growth
- **Leverage**: $132M term loan at 4.7%, $26.5M revolver draw

**【CEO Opening Remarks】**
- CEO Christopher Reading highlighted Q3 2025 results, emphasizing 84 new PT facilities (net of closures) and 32.2 average visits per clinic per day, a record high.
- Noted 18% year-over-year revenue growth, driven by acquisitions and organic expansion, with 84% of growth from new locations.
- Discussed Medicare headwinds ($25M profit impact in 2025) but highlighted resilience, including AI-driven documentation and front-desk virtualization initiatives.

**【CFO Financial Commentary】
- CFO Carey Hendrickson reported:
  - Total revenue $168.1M, +17.8% YoY
  - Gross profit up 30% YoY, despite inflation
  - Salaries and related costs per visit down $0.40 YoY
  - Operating margin 18.6%, up 20bps vs. prior year
  - IIP segment: 15% revenue growth, 11% EBITDA growth
- Noted $132M term loan with 4.7% fixed rate and $26.5M revolver draw.

**【Q&A Highlights】**
- **Demand & Labor**: CEO reported 18% visit growth, with 2.2% increase in mature clinics. Labor costs per visit down 1% YoY despite inflation. 84% of staff retained in 2025.
- **Medicare Outlook 2026**: Expected 1.5-1.7% rate increase, with remote therapeutic monitoring (RTM) poised to add $0.50-$1.00/visit. CMS reduced visit thresholds for RTM eligibility.
- **M&A Strategy**: Prioritized IIP (injury prevention) acquisitions due to higher margins (19.6% vs. PT 18.6%). 2026 focus on RTM and AI tools.
- **Home Care Expansion**: Metro (NYC) home care visits +28% YoY, with Northeast Medicare rates 2x national average. Margins offset higher labor costs via scheduling density.
- **De Novo Growth**: Target 30-50 new clinics/year, constrained by leadership availability. 2026 pipeline includes 11 new work comp contracts.
- **Inflation Impact**: Operating costs +1% YoY, best-in-class control in inflationary environment.

U.S. Physical Therapy, Inc. (USPH) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: 17.3% PT revenue increase, 22.6% IIP growth, and 32.7 visits/clinic/day record.
- **Margin Expansion**: 21.1% gross profit margin, 17.5% EBITDA margin, and $26.9M EBITDA (20% YoY).
- **AI Innovation**: AI tools reduce documentation time, with 250+ clinics using voice recognition.
- **Share Buyback**: $25M authorized to capitalize on undervalued stock.
- **Medicare Fix**: 1-1.75% rate increase proposed for 2026, offsetting $25M annual cuts.

**【CEO Summary Section】**
- **Record Q2 Performance**: Visits per clinic/day reached 32.7, up 6.9% YoY, driven by patient referrals and a Net Promoter Score of 93.5 (vs. industry benchmark of 30-50). 
- **Injury Prevention Growth**: IIP revenues rose 22.6% YoY, with organic growth of 18.4%, targeting large auto industry contracts. 
- **AI Adoption**: Rolled out AI-powered clinical documentation tools in 250+ clinics, reducing documentation time and improving retention. 
- **Medicare Headwinds**: $25M annual impact from rate cuts, but net rate per visit held steady at $105.33 through targeted contract negotiations.

**【CFO Financial Commentary】**
- **Adjusted EBITDA**: $26.9M (up 20% YoY), with margin expanding to 17.5% from 16.4%. Full year guidance raised to $93-97M.
- **Gross Profit Margin**: 21.1% (vs. 20.1% YoY), driven by cost control and 17.3% PT revenue growth.
- **Balance Sheet**: $115M term loan with 4.7% fixed rate, $34.1M cash, and $24.5M drawn on $175M revolver.
- **Share Buyback**: Authorized $25M program, with M&A as primary capital allocation.

**【Q&A Highlights】**
- **Labor Management**: 25% increase in student clinical rotations, 20% reduction in front desk FTEs via AI, and lowest turnover in 7 years.
- **Medicare 2026 Rates**: Proposed 1-1.75% increase ($2M-$3M revenue impact), with focus on musculoskeletal primary care pilot in Maryland.
- **IIP Momentum**: 25+ new contracts pipeline, targeting 10%+ organic growth. 
- **Home Care Expansion**: 28,493 visits Q2, up 24% YoY from Metro PT acquisition.

U.S. Physical Therapy (USPH)-7 Aug 25-2025 Q2 Earnings call transcript

- **Record Q1 Growth**: 16.4% revenue rise to $156.4M, driven by March's 33.2 visits/day and 21%+ margin.
- **IIP Segment Dominance**: 28.8% revenue growth, 29.1% profit growth, with 15.1% organic expansion.
- **Rate Resilience**: +$2.29 net rate vs. 2024, offsetting 2.9% Medicare cut, with workers' comp mix up to 10.9%.
- **Home Care Expansion**: Metro's 50 visits/day model being scaled via acquisitions, with FTE productivity gains.
- **Medicare Advocacy**: Maryland EQIP pilot shows 10-15% cost savings, positioning for fee schedule fix.


**【CEO Summary Section】**
- **Q1 2025 Highlights**: Despite January and February weather disruptions, Q1 visit per clinic/day reached a record 31.4%, with March alone driving a 21%+ margin. Mature clinics saw 29.4% growth in January, rebounding to 33.2% in March.
- **Metro Acquisition Performance**: Metro's visits per clinic/day rose from 44 in January to 50 in March, with strong leadership and operational efficiency.
- **Rate Growth**: Net rate increased $2.29/Q1 vs. 2024, offsetting a 2.9% Medicare cut. Workers' comp revenue mix rose to 10.9% (from 9.3% in 2023).
- **IIP Segment Strength**: IIP revenue grew 28.8% YoY, with 29.1% operating income growth, driven by organic expansion and contract wins in manufacturing.
- **Guidance Update**: Management expects to provide 2025 guidance post-Q2, with Q1 results exceeding internal expectations.

**【CFO Financial Commentary】**
- **Revenue & Profitability**: Physical therapy revenue $156.4M (+16.4% YoY), adjusted EBITDA $21.7M (+16.5% YoY). IIP margin held steady at 20.4%.
- **Cost Management**: Salaries per visit +3.4% YoY (1.4% ex-acquisitions). Total operating cost per visit +4.4% YoY (3% ex-acquisitions).
- **Balance Sheet**: $129.4M term loan with 4.7% effective rate, $39.2M cash, and $175M revolver with $28M drawn.
- **Leverage & Growth**: Acquisitions remain primary capital use, with 14 new clinics opened in Q1.

**【Q&A Key Themes】**
1. **Weather Impact**: 26,000 lost visits in Q1, concentrated in mature clinics. March volumes offset losses, setting up strong H2.
2. **Economic Resilience**: 2008-2009 playbook shows same-store volume decline <2%, with growth via new contracts and cost control.
3. **IIP Growth Drivers**: 100%+ contract renewal rate, organic wins in auto manufacturing, and 15.1% YoY growth ex-acquisitions.
4. **Medicare Advocacy**: EQIP pilot in Maryland shows 10-15% cost savings via PT-led care, potentially offsetting $100B in physician fee schedule cuts.
5. **Home Care Expansion**: Metro's home care model (50+ visits/day) being replicated via acquisitions, with FTE productivity gains.
6. **Pricing Momentum**: Commercial rates +2.1% YoY, workers' comp rates +10%, offsetting Medicare cuts.


U.S. Physical Therapy, Inc. (USPH) Q1 2025 Earnings Call Transcript

- **Revenue Surge**: Q4 2024 revenue up 14.2% YoY to $153.8M, driven by 13% patient volume growth and 2.5% rate increase. Full-year revenue climbed 24%.
- **Cost Efficiency**: Operating cost per visit rose only 1.7% YoY, with AI and virtualization pilots targeting $10M+ annual savings.
- **Acquisition Momentum**: 7 acquisitions in 2024 added 70 clinics, including New York entry. IIP segment grew 32% Q4 and 23.8% YoY.
- **EBITDA Guidance**: 2025 target $88-93M, despite 2.9% Medicare rate cut. Balance sheet remains strong with $41.4M cash and $175M revolver.
- **Home Care Expansion**: Metro's 20% home care mix and virtual tools position for scalable growth in 2025.


**【CEO Summary Section】**
- **Revenue Growth**: Q4 2024 revenue increased 14.2% YoY to $153.8 million, driven by a 13% YoY rise in patient volume and a 2.5% increase in net rate (excluding Medicare and Metro). Full-year revenue grew 24% to $97 million.
- **Patient Satisfaction**: Net Promoter Score of 93 and Google Care rating of 4.9, with 31.7 visits/day/clinic (record high).
- **Cost Management**: Salaries and related costs per visit increased 3.5% YoY, but total operating cost per visit rose only 1.7%. AI-driven note system and virtual front desk pilots aim to reduce overhead.
- **Acquisitions & Expansion**: 7 acquisitions in 2024, adding 70 clinics, including entry into New York via Metro PT. IIP segment grew 32% Q4 and 23.8% YoY.

**【CFO Financial Commentary】**
- **Adjusted EBITDA**: Q4 2024: $21.8 million (15.2% margin), up 14.7% YoY. Full-year: $88 million (15.2% margin).
- **Net Rate**: $104.73/Q4, up $1.05 YoY despite 1.8% Medicare cut. Non-Medicare rate increased 1.4% YoY.
- **EBITDA Guidance 2025**: $88-93 million, reflecting 2.9% Medicare rate reduction ($5.7M EBITDA impact) and $133M deployed in 2024 acquisitions.
- **Balance Sheet**: $140.6M term loan, $175M revolver (11M drawn), $41.4M cash. Dividend increased to $0.45/share.

**【Q&A Highlights】**
- **Medicare Rate Cut**: 2.9% reduction in 2025, offset by commercial rate negotiations and IIP growth. No expectation of legislative relief.
- **Staffing Costs**: 3% visit growth in Q4 2024, targeting 2-3% in 2025. Virtual front desk and AI pilots aim to reduce $10M+ in annual costs.
- **Metro PT Integration**: 50% ownership, $10M Q4 revenue, lower rate ($102.54 vs. $104.73). Full-year EBITDA contribution ~$6M. Rate improvements expected in 2025.
- **IIP Growth**: 32% Q4 revenue growth, 15.6% YoY. New 50-FTE auto manufacturer contract drove margin compression but long-term upside.
- **Home Care Expansion**: Metro's 20% home care mix offers expansion opportunities. Piloting virtual front desk and AI tools to scale efficiently.


Actual											0.3	0.39	0.86	0.85	0.64	0.96	0.85	0.72	0.65	0.9	0.58	0.58	0.59	0.76	0.62	0.59	0.51	0.73	0.69	0.51	0.48	0.81	0.66	0.67
Forecast											0.402	-0.18	0.512	0.832	0.47	0.726	0.778	0.688	0.626	0.946	0.628	0.57	0.5459	0.748	0.6165	0.5661	0.5578	0.8186	0.684	0.6886	0.4305	0.7152	0.6696	0.6754
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-25.37%	+316.67%	+67.97%	+2.16%	+36.17%	+32.23%	+9.25%	+4.65%	+3.83%	-4.86%	-7.64%	+1.75%	+8.08%	+1.60%	+0.57%	+4.22%	-8.57%	-10.82%	+0.88%	-25.94%	+11.50%	+13.26%	-1.43%	-0.80%

USPH

USPH fundamentals

USPH Q4 2025 Earnings

Earnings Call

You can ask Aime

USPH

USPH fundamentals

USPH Q4 2025 Earnings

Earnings Call

USPH Earnings Call Summary for Q4/202510:30 AM on Feb 26, 2026

USPH Earnings Call Summary for Q3/202510:30 AM on Nov 6, 2025

USPH Earnings Call Summary for Q2/202510:30 AM on Aug 7, 2025

USPH Earnings Call Summary for Q1/202510:30 AM on May 8, 2025

USPH Earnings Call Summary for Q4/202410:30 AM on Feb 27, 2025

You can ask Aime